Lataa...
First-line treatment of metastatic melanoma: role of nivolumab
Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape with increased survival rates and the real possibility that long-term disease control is achievable....
Tallennettuna:
| Julkaisussa: | Immunotargets Ther |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315343/ https://ncbi.nlm.nih.gov/pubmed/28243579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S110479 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|